pamidronate has been researched along with Carcinoma in 11 studies
Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC) patients with at least 1 osteolytic lesion based on data from a Phase III, randomized trial." | 9.11 | Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. ( Chen, BL; Coleman, RE; Dugan, W; Eisenberg, PD; Gordon, DH; Kaminski, M; Major, P; Provencher, L; Rosen, LS; Seaman, J; Simeone, J, 2004) |
| "To identify markers sensitive to inhibitors of the farnesylation pathway, we used 3 breast cancer cell lines (SKBR-3, MDA-175, and MDA-231) to evaluate the in vitro effects of pamidronate, an inhibitor of farnesyl diphosphate synthase." | 7.72 | Pamidronate resistance and associated low ras levels in breast cancer cells: a role for combinatorial therapy. ( Blasick, TM; Brown, RE; Lun, M; Siegelmann-Danieli, N; Zhang, PL, 2004) |
| "Pamidronate is an effective drug used not only in patients with tumor-associated hypercalcemia, but also in normocalcemic patients with metastatic bone disease to relieve pains." | 5.30 | Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate. ( Alakavuklar, M; Biberoglu, S; Cömlekçi, A; Hekimsoy, Z; Okan, I; Pişkin, O; Sekeroglu, B, 1998) |
| "Parathyroid carcinoma is rare and the associated hypercalcaemia is often resistant to all treatment." | 5.29 | Prolonged remission of hypercalcaemia due to parathyroid carcinoma with pamidronate. ( Braatvedt, GD; Corrall, RJ; Newrick, PG; Sheffield, E; Webb, AJ, 1994) |
| "Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC) patients with at least 1 osteolytic lesion based on data from a Phase III, randomized trial." | 5.11 | Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. ( Chen, BL; Coleman, RE; Dugan, W; Eisenberg, PD; Gordon, DH; Kaminski, M; Major, P; Provencher, L; Rosen, LS; Seaman, J; Simeone, J, 2004) |
| " Pamidronate, an inhibitor of bone resorption used primarily in the management of tumor-induced hypercalcemia and Paget's disease, is reported to cause conjunctivitis, anterior uveitis, and infrequently episcleritis and scleritis." | 3.72 | Posterior uveitis: an under-recognized adverse effect of pamidronate: 2 case reports. ( Claes, C; Haverbeke, G; Pertile, G; Zeyen, T, 2003) |
| "To identify markers sensitive to inhibitors of the farnesylation pathway, we used 3 breast cancer cell lines (SKBR-3, MDA-175, and MDA-231) to evaluate the in vitro effects of pamidronate, an inhibitor of farnesyl diphosphate synthase." | 3.72 | Pamidronate resistance and associated low ras levels in breast cancer cells: a role for combinatorial therapy. ( Blasick, TM; Brown, RE; Lun, M; Siegelmann-Danieli, N; Zhang, PL, 2004) |
| "We present a case of undifferentiated pancreatic cancer associated with humoral hypercalcemia of malignancy (HHM) in which parathyroid hormone-related protein (PTH-rP) is identified as the causative factor of hypercalcemia." | 2.40 | Undifferentiated pancreatic cancer associated with humoral hypercalcemia of malignancy. ( Higuchi, T; Kakizaki, S; Kitazawa, R; Mori, M; Nagamine, T; Ohya, N; Takagi, H; Takayama, H; Yoshinaga, T, 1998) |
| "Pamidronate is an effective drug used not only in patients with tumor-associated hypercalcemia, but also in normocalcemic patients with metastatic bone disease to relieve pains." | 1.30 | Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate. ( Alakavuklar, M; Biberoglu, S; Cömlekçi, A; Hekimsoy, Z; Okan, I; Pişkin, O; Sekeroglu, B, 1998) |
| "Parathyroid carcinoma is rare and the associated hypercalcaemia is often resistant to all treatment." | 1.29 | Prolonged remission of hypercalcaemia due to parathyroid carcinoma with pamidronate. ( Braatvedt, GD; Corrall, RJ; Newrick, PG; Sheffield, E; Webb, AJ, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (45.45) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pittaway, JF | 1 |
| Srirangalingam, U | 1 |
| Hanson, PL | 1 |
| Jones, P | 1 |
| Drake, WM | 1 |
| Rosen, LS | 1 |
| Gordon, DH | 1 |
| Dugan, W | 1 |
| Major, P | 1 |
| Eisenberg, PD | 1 |
| Provencher, L | 1 |
| Kaminski, M | 1 |
| Simeone, J | 1 |
| Seaman, J | 1 |
| Chen, BL | 1 |
| Coleman, RE | 1 |
| Haverbeke, G | 1 |
| Pertile, G | 1 |
| Claes, C | 1 |
| Zeyen, T | 1 |
| Zhang, PL | 1 |
| Lun, M | 1 |
| Siegelmann-Danieli, N | 1 |
| Blasick, TM | 1 |
| Brown, RE | 1 |
| Hay, KD | 1 |
| Bishop, PA | 1 |
| Engroff, SL | 1 |
| Kim, DD | 1 |
| Newrick, PG | 1 |
| Braatvedt, GD | 1 |
| Webb, AJ | 1 |
| Sheffield, E | 1 |
| Corrall, RJ | 1 |
| Vainas, IG | 1 |
| Tsilikas, C | 1 |
| Grecu, A | 1 |
| Pasaitu, K | 1 |
| Stergiou, I | 1 |
| Kortsaris, AH | 1 |
| Cascinu, S | 1 |
| Graziano, F | 1 |
| Alessandroni, P | 1 |
| Ligi, M | 1 |
| Del Ferro, E | 1 |
| Rossi, D | 1 |
| Ficarelli, R | 1 |
| Catalano, G | 1 |
| Cömlekçi, A | 1 |
| Biberoglu, S | 1 |
| Hekimsoy, Z | 1 |
| Okan, I | 1 |
| Pişkin, O | 1 |
| Sekeroglu, B | 1 |
| Alakavuklar, M | 1 |
| Kakizaki, S | 1 |
| Ohya, N | 1 |
| Yoshinaga, T | 1 |
| Higuchi, T | 1 |
| Kitazawa, R | 1 |
| Takayama, H | 1 |
| Takagi, H | 1 |
| Nagamine, T | 1 |
| Mori, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for pamidronate and Carcinoma
| Article | Year |
|---|---|
Metastatic parathyroid carcinoma (mPCa): natural history and treatment of a case.
Topics: Antineoplastic Agents; Calcitonin; Carcinoma; Diagnosis, Differential; Diphosphonates; Humans; Lung | 1997 |
Undifferentiated pancreatic cancer associated with humoral hypercalcemia of malignancy.
Topics: Antineoplastic Agents; Carcinoma; Diphosphonates; Humans; Hypercalcemia; Liver Neoplasms; Male; Midd | 1998 |
2 trials available for pamidronate and Carcinoma
| Article | Year |
|---|---|
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma; Diphosphonates; Dose-Response Re | 2004 |
Different doses of pamidronate in patients with painful osteolytic bone metastases.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Diphosphonates; Female; Humans; Male; | 1998 |
7 other studies available for pamidronate and Carcinoma
| Article | Year |
|---|---|
Renal replacement therapy as a treatment for severe refractory hypercalcemia.
Topics: Adenoma; Adult; Carcinoma; Cinacalcet; Diphosphonates; Drug Resistance; Emergencies; Female; Furosem | 2014 |
Posterior uveitis: an under-recognized adverse effect of pamidronate: 2 case reports.
Topics: Bone Neoplasms; Bone Resorption; Carcinoma; Conjunctivitis; Diphosphonates; Fatal Outcome; Humans; M | 2003 |
Pamidronate resistance and associated low ras levels in breast cancer cells: a role for combinatorial therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Br | 2004 |
Association of osteonecrosis of the jaws and bisphosphonate pharmacotherapy: dental implications.
Topics: Adenocarcinoma; Aged, 80 and over; Bone Density Conservation Agents; Carcinoma; Diabetes Mellitus, T | 2006 |
Treating bisphosphonate osteonecrosis of the jaws: is there a role for resection and vascularized reconstruction?
Topics: Bone Density Conservation Agents; Bone Plates; Bone Transplantation; Breast Neoplasms; Carcinoma; Di | 2007 |
Prolonged remission of hypercalcaemia due to parathyroid carcinoma with pamidronate.
Topics: Calcium; Carcinoma; Diphosphonates; Female; Humans; Hypercalcemia; Middle Aged; Pamidronate; Parathy | 1994 |
Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate.
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Carcinoma; Diphosphonates; | 1998 |